Artificial intelligence-powered digital pathology model supports that fibrosis is reduced by semaglutide in patients with NASH

Significantly greater number of primary endpoint responders is detected in treated vs. placebo arms by AIM-NASH but not manual AIM-NASH detected dose-dependent treatment response in Ph2 study, in addition a statistically significant difference in proportion of subjects achieving endpoints.